HUTCHMED Completes Rolling Submission of NDA to FDA for Fruquintinib HUTCHMED (China) Limited announced the completion of the rolling submission of a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") for fruquintinib, its highly selective and potent oral inhibitor of VEGFR-1,...
Find MoreAge-related hearing loss (ARHL), also known as presbycusis, is a complicated disease that has been observed in tens of millions of people around the world. It is defined as a progressive, irreversible, and symmetrical bilateral neurosensory hearing loss caused by cochlea degeneration, in which sound-induced vibrati...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.